Viridian Strengthens Position with Japanese Licensing Deal for Thyroid Eye Disease Treatments
Deal News | Jul 31, 2025 | Ropes & Gray
Viridian Therapeutics has entered into a significant licensing and collaboration agreement with Kissei Pharmaceutical to develop and commercialize thyroid eye disease treatments, veligrotug and VRDN-003, effectively expanding its market reach into Japan. Announced on July 30th, the transaction enables Viridian to receive a $70 million upfront payment, with additional potential earnings of $315 million in milestone payments. The deal further includes tiered royalties based on net sales within Japan. Legal guidance for Viridian was provided by Ropes & Gray, with specific oversight from life sciences licensing partner Hannah England, assisted by associates Nicole Rohr and Ryan Kramer, with tax partner David Saltzman also contributing.
Sectors
- Biotechnology
- Pharmaceuticals
- Legal Advisory
Geography
- Japan – The geographic focus of the deal is Japan, where the thyroid eye disease therapies will be developed and marketed under the licensing agreement.
Industry
- Biotechnology – This industry is relevant as Viridian Therapeutics is focused on the development of treatments for thyroid eye disease, a part of the biotechnology sector's research and drug development.
- Pharmaceuticals – Kissei Pharmaceutical's involvement underscores the relevance of this industry, as they specialize in the development and distribution of medical therapies in Japan.
- Legal Advisory – Ropes & Gray's role in advising the deal highlights the significance of legal advisory services in structuring and negotiating complex licensing agreements.
Financials
- $70 million – Upfront payment received by Viridian Therapeutics from Kissei Pharmaceutical.
- $315 million – Potential milestone payments Viridian Therapeutics could receive based on agreed-upon conditions.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Viridian Therapeutics | Licensor | Company | A biotechnology company developing thyroid eye disease treatments. |
| Kissei Pharmaceutical | Licensee | Company | A Japanese pharmaceutical company focusing on the development and marketing of medical therapies in Japan. |
| Ropes & Gray | Legal Advisor | Company | A law firm providing legal advisory services for the deal, led by their life sciences licensing team. |
| Hannah England | Life Sciences Licensing Partner | Person | Lead legal advisor from Ropes & Gray for the licensing deal. |